Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 1,745 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $10.00, for a total value of $17,450.00. Following the completion of the transaction, the insider now owns 32,253 shares of the company's stock, valued at $322,530. The trade was a 5.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Barry Ticho also recently made the following trade(s):
- On Tuesday, June 3rd, Barry Ticho sold 6,471 shares of Stoke Therapeutics stock. The stock was sold at an average price of $10.03, for a total value of $64,904.13.
- On Tuesday, March 18th, Barry Ticho sold 3,884 shares of Stoke Therapeutics stock. The stock was sold at an average price of $8.67, for a total value of $33,674.28.
Stoke Therapeutics Price Performance
Stoke Therapeutics stock traded up $0.04 during trading hours on Wednesday, hitting $10.94. The stock had a trading volume of 598,670 shares, compared to its average volume of 705,127. The stock has a market capitalization of $597.29 million, a price-to-earnings ratio of -5.21 and a beta of 1.20. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58. The stock's fifty day moving average is $8.51 and its two-hundred day moving average is $9.66.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.
Institutional Trading of Stoke Therapeutics
A number of hedge funds have recently added to or reduced their stakes in STOK. Toronto Dominion Bank acquired a new stake in Stoke Therapeutics in the 4th quarter worth about $35,001,000. RTW Investments LP boosted its stake in Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock worth $56,512,000 after buying an additional 471,240 shares during the last quarter. Checkpoint Capital L.P. boosted its stake in Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock worth $4,859,000 after buying an additional 425,330 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in Stoke Therapeutics in the 1st quarter worth about $2,670,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Stoke Therapeutics in the 1st quarter worth about $2,376,000.
Wall Street Analysts Forecast Growth
STOK has been the subject of several research analyst reports. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. HC Wainwright lowered their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Chardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $23.20.
Read Our Latest Analysis on Stoke Therapeutics
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
